
Total number of projects: 6
As coordinator: 0
As participant: 6
Sole participant: 0
Coordinator / Participant Ratio: 0*
| Total project funding [€]: | Projects [No]: | |||||
|---|---|---|---|---|---|---|
| Year: | coordinator* | participant* | per partner | as coordinator | as participant | |
| 2013 | 0 | 11.474.821 | 531.401 | 2 | ||
| 2012 | 0 | 12.805.026 | 1.169.663 | 3 | ||
| 2011 | 0 | 5.999.998 | 333.556 | 1 | ||
Total number of partners: 55
Partner loyalty:
Frequent Partner: (> 2 projects): 0
Rare Partner: 55
Frequent / Rare Partner Ratio: 0
| Start date | Project | acronym | role | funding | partners |
|---|---|---|---|---|---|
| 2013-11-01 | Clinical Studies on a Multivalent Vaccine for Human Visceral Leishmaniasis | MULEVACLIN | participant | 5.475.364 | 8 |
| 2013-10-01 | "A “Universal” Influenza Vaccine through Synthetic, Dendritic Cell-Targeted, Self-Replicating RNA Vaccines" | UNIVAX | participant | 5.999.457 | 11 |
| 2012-10-01 | Development of an oral Helicobacter Pylori vaccine | HELICOVAXOR | participant | 1.303.000 | 11 |
| 2012-10-01 | Microbicide Optimization Through Innovative Formulation for Vaginal and Rectal Delivery | MOTIF | participant | 5.818.937 | 9 |
| 2012-01-01 | Novel Bone Morphogenetic Protein-6 Biocompatible Carrier Device for Bone Regeneration | OSTEOGROW | participant | 5.683.089 | 11 |
| 2011-06-01 | Innovative anti-influenza drugs excluding viral escape | ANTIFLU | participant | 5.999.998 | 11 |